ARECOR THERAPEUTICS PLC Business Segments Arecor Therapeutics plc
Equities
AREC
GB00BMWLM973
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.00 GBX | 0.00% |
|
-1.84% | -56.16% |
| 09-11 | Arecor Therapeutics plc Presents Positive Data from Phase I Clinical Trial of Ultra-Concentrated, Ultra-Rapid Acting Insulins | CI |
| 07-23 | Arecor Therapeutics Completes Retail Offer | MT |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
Biological Products | ||||||
Biotechnology | 748K | 1.7M | 1.16M | 2.4M | 4.57M | |
Total Assets | 5.45M | 4.28M | 20.92M | 21.76M | 15.38M | |
Interest Expense | -23.98K | -82K | -22K | -26K | -15K | |
Income Tax Expense | -435K | -760K | -776K | -1.28M | -347K | |
CAPEX | -73.13K | -52.29K | -69K | -345K | -151K | |
EBT | -2.87M | -3.51M | -6.94M | -10.54M | -8.9M | |
Gross Profit | 748K | 1.7M | - | - | - | |
D&A | 167K | 169K | 171K | 339K | 487K | |
Operating Income | -2.86M | -3.43M | -6.44M | -10.63M | -9.18M | |
Net Income | -2.44M | -2.75M | -6.17M | -9.26M | -8.55M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
UK | 44.9K | - | 71K | 1.14M | 2.89M | |
USA | - | - | 940K | 784K | 556K | |
Switzerland | - | - | - | 240K | 488K | |
Germany | - | - | - | - | 332K | |
Italy | - | - | - | - | 274K | |
India | - | - | - | 135K | 30K | |
Rest of World | 380K | 962K | 71K | - | - | |
Rest of Europe | 322K | 736K | 76K | 108K | - |
- Stock Market
- Equities
- AREC Stock
- Financials Arecor Therapeutics plc
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition